الصفحة الرئيسية>>Phenylacetyl-(D-Arg²·²⁸,p-chloro-Phe⁶,Homoarg⁹·²⁹,Tyr(Me)¹⁰,Abu¹⁵,Nle²⁷)-GRF (1-29) amide (human)

Phenylacetyl-(D-Arg²·²⁸,p-chloro-Phe⁶,Homoarg⁹·²⁹,Tyr(Me)¹⁰,Abu¹⁵,Nle²⁷)-GRF (1-29) amide (human)

رقم الكتالوجGA23360

JV-1-38 exhibited antagonistic activity against human growth hormone-releasing hormone (hGH-RH) slightly less potent than JV-1-36 (H-4884) both in vitro and in vivo but proved to be very long-acting in vivo, suppressing the GH-RH induced GH release even after 60 min. Antagonists of this structure are possible candidates for clinical application in the treatment of cancers dependent on insulin-like growth factors I and II.

Products are for research use only. Not for human use. We do not sell to patients.

Phenylacetyl-(D-Arg²·²⁸,p-chloro-Phe⁶,Homoarg⁹·²⁹,Tyr(Me)¹⁰,Abu¹⁵,Nle²⁷)-GRF (1-29) amide (human) التركيب الكيميائي

Cas No.: 221377-79-3

الحجم السعر المخزون الكميّة
0.5mg
1130٫00
متوفر
1mg
2032٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

JV-1-38 exhibited antagonistic activity against human growth hormone-releasing hormone (hGH-RH) slightly less potent than JV-1-36 both in vitro and in vivo but proved to be very long-acting in vivo, suppressing the GH-RH induced GH release even after 6

مراجعات

Review for Phenylacetyl-(D-Arg²·²⁸,p-chloro-Phe⁶,Homoarg⁹·²⁹,Tyr(Me)¹⁰,Abu¹⁵,Nle²⁷)-GRF (1-29) amide (human)

Average Rating: 5 ★★★★★ (Based on Reviews and 18 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Phenylacetyl-(D-Arg²·²⁸,p-chloro-Phe⁶,Homoarg⁹·²⁹,Tyr(Me)¹⁰,Abu¹⁵,Nle²⁷)-GRF (1-29) amide (human)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.